Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Adenosine
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Dosage === When used to treat SVT, adenosine is administered [[Intravenous therapy|intravenously]] as a rapid [[Bolus (medicine)|bolus]] (typically 0.10β0.15 mg/kg initially) over 1-2 seconds, followed by a rapid [[saline flush]] (often using a 2-way or 3-way stopcock). If the initial dose is ineffective, it may be repeated every 2 minutes with a slightly increased dose (0.05β0.1 mg/kg increments) every 2 minutes up to a maximum total dose of 0.3 mg/kg (not exceeding 12 mg). Due to adenosine's extremely short half-life (less than 10 seconds), it is often injected through a [[central venous line]] or a large proximal peripheral vein; administration into lower extremities, [[PICC line]]s, or smaller veins may lead to therapeutic failure due to rapid metabolism before reaching the heart.<ref name="pmid39033975"/> When given to dilate the arteries, such as in a "stress test", the dosage is typically 0.14 mg/kg/min, administered for 4 or 6 minutes, depending on the protocol. The recommended dose may be increased in patients on theophylline since methylxanthines prevent binding of adenosine at receptor sites. The dose is often decreased in patients on [[dipyridamole]] (Persantine) and [[diazepam]] (Valium) because adenosine potentiates the effects of these drugs. The recommended dose is also reduced by half in patients presenting [[congestive heart failure]], [[myocardial infarction]], [[shock (circulatory)|shock]], [[hypoxia (medical)|hypoxia]], and/or chronic liver disease or [[chronic kidney disease]], and in [[elderly]] patients.
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)